Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPĪ± (Signal
Regulatory Protein Alpha) and enhances the phagocytosis of cancer cells by macrophages. This
is a study to evaluate the safety, tolerability and effectiveness of TQB2928 injection in
subjects with advanced malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.